INTRODUCTION
VIRUS, DISEASE, INFLUENZA
The COVID-19 pandemic has had a devastating impact on global health, resulting in unprecedented levels of mortality and morbidity. To combat the severity of the disease, various oral antiviral agents have been developed and proven effective in preventing severe cases of COVID-19, namely, nirmatrelvir/ritonavir and molnupiravir (Sotrovimab (VIR-7831) was a neutralizing monoclonal antibody (NmAb), which many RCTs demonstrated preventing hospitalization in outpatient COVID-19; however, there were many gaps in NmAb treatment, including the high cost and difficulty of access (The COVID-19 convalescent plasma (CCP) transfusion was reported to treat MERS-CoV, SARS-CoV-1, and influenza virus (The favorable outcomes of CPT were demonstrated in those who received early high neutralizing antibody titer CPT in outpatient treatment and early course in severe COVID-19 (This study aimed to evaluate the efficacy of combined high neutralizing antibody titer CPT with favipiravir (CPT-FPV) and evaluated the non-inferiority to sotrovimab in preventing hospitalization in mild-to-moderate COVID-19 with outpatient treatment.